Table 1

Baseline clinical characteristics of the patients with CD and UC

Baseline clinical characteristicsCD Spanish cohort (n=34)CD Belgian cohort (n=53)Comparison between cohorts (p value)
Male/female (%)13/21 (38.2/61.7)28/25 (52.8/47.2)0.201
Median (IQR) age at surgery (years) or at sample collection34 (18 –58)41.3 (26.5–52.9)0.141
Median duration of disease (IQR) at surgery (years) or at sampling6.5 (0–28)15.7 (4.1–27.1)0.0002
Maximum disease location (Montreal classification)0.682
 L1 ileal (%)12 (35)18 (34)
 L2 colonic (%)0 (0)0 (0)
 L3 ileocolonic (%)22 (64.7)35 (66)
 L4 isolated upper disease (%)2 (5.8)2 (3.8)
Disease behaviour at surgery (Montreal classification)0.009
 B1 non-stricturing, non-penetrating (%)3 (8.8)2 (3.8)
 B2 stricturing (%)22 (64.7)21 (39.6)
 B3 penetrating (%)5 (14.7)30 (56.6)
 p perianal disease (%)3 (8.8)15 (28.3)
Active smoking at surgery (%)10 (29.4)16 (30.2)0.012
Medication at surgery or at sampling
 Mesalamine–sulfasalazine (%)4 (11.8)4 (7.5)0.012
 Corticosteroids (%)2 (2.9)10 (18.9)0.183
 Immunosuppressants (%)14 (41.1)12 (22.6)0.087
 Anti-TNF (%)12 (23.5)7 (13.2)0.023
 Antibiotics (%)0 (0)9 (16.9)0.033
 Methotrexate1 (2.9)
 Other10 (29.4)
 None1 (2.9)
UC Spanish cohort 1 (n=33)UC Spanish cohort 2 (n=41)
Male/female (%)9/24 (27.2/72.7)17/24 (41.4/58.5)0.595
Median (IQR) age at sample collection43 (24–62)43 (24–68)0.500
Median duration of disease (IQR) at sampling9 (1–23)10 (1–34)0.392
Disease behaviour at sampling0.208
 E1 proctitis9 (27.3)18 (43.9)
 E2 left sided colitis11 (33.3)10 (24.4)
 E3 pancolitis13 (39.4)13 (31.7)
Medication at sampling
 Mesalamine (%)11 (24)26 (63.4)0.021
 Corticosteroids (%)2 (6)00.617
 Immunosuppressants (%)8 (24)00.026
 Other2 (6)3 (7.3)0.708
 None2 (4.8)
  • Comparison between cohorts have been performed; the χ2 test was applied to categorical variables, and the t-test was applied to continuous variables; when p<0.05 differences were considered significant.

  • CD, Crohn's disease; TNF, tumour necrosis factor.